CD19 and leukemia: In a landmark study, Themeli et al. demonstrated that induced PSCs (iPSCs) reprogrammed from a T cell clone could be differentiated into cytotoxic CAR T cells in vitro.91 Although these PSC-derived T cells had functional properties more akin to γσ, as opposed to αβ-T cells, they were capable of eradicating CD19+ tumor cells in vitro and in a xenograft leukemia model.91